News
05 Mar 2025
CollaborateAntibodyImmunotherapyADC
24 Feb 2025
24 Feb 2025
24 Feb 2025
21 Feb 2025
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer
21 Feb 2025
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
IPO
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
Clinical ResultAHAASH
20 Feb 2025
20 Feb 2025